

Datasheet: PHP042

Description:	RECOMBINANT HUMAN INTERLEUKIN-2
Name:	IL-2
Format:	Rec. Protein
Product Type:	Recombinant Protein
Quantity:	50 µg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			0.2 - 0.4ng/well
Western Blotting	▪			1.5 - 3.0ng/lane
Functional Assays	▪			0.1ng/ml - 2.0ng/ml

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species

Human

Species Cross Reactivity

Reacts with: Cynomolgus monkey, Rhesus Monkey, Dolphin
N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.

Product Form

Purified protein produced in *E. coli* - lyophilized

Reconstitution

Reconstitute with 0.5 ml 0.1M acetic acid. Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution.

Buffer Solution

10mM Sodium citrate

Preservative Stabilisers

None present

Carrier Free	Yes
Endotoxin Level	< 0.1 ng/ug
Approx. Protein Concentrations	Total protein concentration 0.1 mg/ml after reconstitution
External Database Links	<p>UniProt: P60568 Related reagents</p> <p>Entrez Gene: 3558 IL2 Related reagents</p>
Product Information	Recombinant human interleukin 2 is an <i>Escherichia coli</i> -derived recombinant protein corresponding to full-length mature human interleukin-2, a secreted peptide required for T-cell proliferation. This preparation has an ED50 of 0.1ng/ml as determined by the dose-dependent stimulation of the proliferation of murine CTLL-2 cells.
Protein Molecular Weight	15.4kDa (134 Amino acid sequence)
Activity	1 x 10 ⁷ units/mg
Purity	>98% by SDS PAGE and HPLC analysis
ELISA	Recombinant Rat interleukin-2 may be used as a standard for ELISA applications with Rat anti Human IL-2 antibody, clone MQ1-17H12 (MCA1553).
Western Blotting	Recombinant human IL-2 may be used as a positive control for Western Blotting applications using Rabbit anti Human IL-2 antibodies (AAR38) for detection
References	<ol style="list-style-type: none"> 1. Akari, H. <i>et al.</i> (2000) Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation. J. Virol. 74 (6): 2907 - 2912. 2. Chan, P.K. <i>et al.</i> (2010) T-cell response to human papillomavirus type 58 L1, E6 and E7 peptides in women with cleared infection, cervical intraepithelial neoplasia and invasive cancer. Clin Vaccine Immunol. 17: 1315-21. 3. Doi, N. <i>et al.</i> (2010) Growth ability in various macaque cell lines of HIV-1 with simian cell-tropism. J Med Invest. 57: 284-92. 4. Vaughan, K. <i>et al.</i> (2007) A DNA vaccine against dolphin morbillivirus is immunogenic in bottlenose dolphins. Vet Immunol Immunopathol. 120: 260-6. 5. Ban, S.A. <i>et al.</i> (2014) Combined immunodeficiency evolving into predominant CD4+ lymphopenia caused by somatic chimerism in JAK3. J Clin Immunol. 34 (8): 941-53. 6. Geoghegan, V. <i>et al.</i> (2015) Comprehensive identification of arginine methylation in primary T cells reveals regulatory roles in cell signalling. Nat Commun. 6: 6758. 7. Yutani, S. <i>et al.</i> (2017) Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies. Cancer Sci. 108 (9): 1732-8.

8. Hirakawa, Y. *et al.* (2019) Immunological consequences following splenectomy in patients with liver cirrhosis. [Exp Ther Med. 18 \(1\): 848-856.](#)

Storage Prior to reconstitution store at -20°C. Following reconstitution store at -20°C.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee Guaranteed for 3 months from the date of reconstitution or until the date of expiry, whichever comes first. Please see label for expiry date.

Health And Safety Information Material Safety Datasheet documentation #10527 available at: 10527: <https://www.bio-rad-antibodies.com/uploads/MSDS/10527.pdf>

Regulatory For research purposes only

North & South America Tel: +1 800 265 7376
Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M395206:220323'

Printed on 23 Mar 2022

© 2022 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)